Authors: SLAYTER KL LUDWIG EA LEW KH MIDDLETON E FERRY JJ JUSKO WJ

Citation: Kl. Slayter et al., ORAL-CONTRACEPTIVE EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS ANDPHARMACODYNAMICS, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 312-321

Authors: JUSKO WJ MILAD MA LUDWIG EA LEW KH KOHLI RK

Citation: Wj. Jusko et al., METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS IN CHRONIC-RENAL-FAILURE, Clinical nephrology, 43, 1995, pp. 16-19

Authors: SLAYTER KL LUDWIG EA LEW KH MIDDLETON E FERRY JJ JUSKO WJ

Citation: Kl. Slayter et al., ORAL-CONTRACEPTIVE EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS ANDPHARMACODYNAMICS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 182-182

Authors: LEW KH JUSKO WJ

Citation: Kh. Lew et Wj. Jusko, PHARMACODYNAMIC MODELING OF CORTISOL SUPPRESSION FROM FLUOCORTOLONE, European Journal of Clinical Pharmacology, 45(6), 1993, pp. 581-583

Authors: LEW KH LUDWIG EA MILAD MA DONOVAN K MIDDLETON E FERRY JJ JUSKO WJ

Citation: Kh. Lew et al., GENDER-BASED EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS, Clinical pharmacology and therapeutics, 54(4), 1993, pp. 402-414